Placenta power: could mitochondria transplants fix bone marrow failure?

NCT ID NCT06465160

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 21 times

Summary

This early-stage study tests a new treatment called MNV-201 for people with low-risk myelodysplastic syndrome (MDS), a bone marrow disorder that causes low blood counts. The therapy uses the patient's own blood stem cells enriched with mitochondria from donated placentas to try to improve blood cell production. The main goal is to check safety, but researchers will also see if it reduces the need for blood transfusions. About 15 adults with anemia who rely on transfusions will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shaare Zedek Medical Center

    RECRUITING

    Jerusalem, Israel, 9103102, Israel

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.